CTOs on the Move

Triumvira

www.triumvira.com

 
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Donna Rill
Chief Technology Officer Profile

Funding

Triumvira raised $55M on 08/27/2020

Similar Companies

Evelo Biosciences

Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. Monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. These new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. Monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. By finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, Evelo can improve the speed, cost and success of drug discovery and development. Evelo`s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. Evelo Biosciences was conceived and created within VentureLabs®, Flagship Pioneering`s institutional innovation foundry, and launched by Flagship in 2015.

Codagenix

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells.

Allergene

Allergene is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sojournix

Sojournix is a clinical stage pharmaceutical company focused on creating new medicines to improve the treatment of women’s health and neuroendocrine disorders.

In Vivo Scientific

In Vivo Scientific is a Valley Park, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.